These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9668372)

  • 21. Clinical applications of pharmacologic therapies for spinal cord injury.
    Zeidman SM; Ling GS; Ducker TB; Ellenbogen RG
    J Spinal Disord; 1996 Oct; 9(5):367-80. PubMed ID: 8938604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is ganglioside GM1 effective in the treatment of stroke?
    Braune S
    Drugs Aging; 1991 Jan; 1(1):57-66. PubMed ID: 1794005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
    Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
    Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
    Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
    Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxic-ischemic damage and the neuroprotective effects of GM1 ganglioside.
    Leon A; Lipartiti M; Seren MS; Lazzaro A; Mazzari S; Koga T; Toffano G; Skaper SD
    Stroke; 1990 Nov; 21(11 Suppl):III95-7. PubMed ID: 2237992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monosialoganglioside effects following cerebral ischemia: relationship with anti-neuronotoxic and pro-neuronotrophic effects.
    Lipartiti M; Seren MS; Lazzaro A; Koga T; Mazzari S; Facci L; Fusco M; Toffano G; Leon A
    Acta Neurobiol Exp (Wars); 1990; 50(4-5):489-94. PubMed ID: 2130663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of Ginkgo biloba on functional outcome of patients with acute ischemic stroke: a double-blind, placebo-controlled, randomized clinical trial.
    Oskouei DS; Rikhtegar R; Hashemilar M; Sadeghi-Bazargani H; Sharifi-Bonab M; Sadeghi-Hokmabadi E; Zarrintan S; Sharifipour E
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e557-63. PubMed ID: 23871729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summary statement: the Sygen(GM-1 ganglioside) clinical trial in acute spinal cord injury.
    Fehlings MG; Bracken MB
    Spine (Phila Pa 1976); 2001 Dec; 26(24 Suppl):S99-100. PubMed ID: 11805615
    [No Abstract]   [Full Text] [Related]  

  • 29. Trafermin for stroke recovery: is it time for another randomized clinical trial?
    Paciaroni M; Bogousslavsky J
    Expert Opin Biol Ther; 2011 Nov; 11(11):1533-41. PubMed ID: 21883031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gangliosides (GM1 and AGF2) reduce mortality due to ischemia: protection of membrane function.
    Karpiak SE; Li YS; Mahadik SP
    Stroke; 1987; 18(1):184-7. PubMed ID: 3027926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Past, present and future of neuroprotection].
    Mracek J
    Cas Lek Cesk; 2010; 149(12):586-90. PubMed ID: 21387585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ganglioside GM1 in early strokes].
    Kuczyńska-Zardzewiały A; Kruszewska J; Lechowicz W; Członkowska A
    Neurol Neurochir Pol; 1994; 28(5):643-9. PubMed ID: 7862232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the ganglioside GM1 on neurologic function, electroencephalogram amplitude, and histology in chronic middle cerebral artery occlusion in cats.
    Komatsumoto S; Greenberg JH; Hickey WF; Reivich M
    Stroke; 1988 Aug; 19(8):1027-35. PubMed ID: 3400101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GM1 ganglioside treatment after global ischemia protects changes in membrane fatty acids and properties of Na+, K+-ATPase and Mg2+-ATPase.
    Mahadik SP; Hawver DB; Hungund BL; Li YS; Karpiak SE
    J Neurosci Res; 1989 Nov; 24(3):402-12. PubMed ID: 2531806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.
    Bornstein NM; Guekht A; Vester J; Heiss WD; Gusev E; Hömberg V; Rahlfs VW; Bajenaru O; Popescu BO; Muresanu D
    Neurol Sci; 2018 Apr; 39(4):629-640. PubMed ID: 29248999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial.
    Hong JM; Choi MH; Sohn SI; Hwang YH; Ahn SH; Lee YB; Shin DI; Chamorro Á; Choi DW;
    Trials; 2018 Jul; 19(1):375. PubMed ID: 30005644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
    Weir CJ; Kaste M; Lees KR;
    Stroke; 2004 Sep; 35(9):2111-6. PubMed ID: 15243146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GM1 Ganglioside: Past Studies and Future Potential.
    Aureli M; Mauri L; Ciampa MG; Prinetti A; Toffano G; Secchieri C; Sonnino S
    Mol Neurobiol; 2016 Apr; 53(3):1824-1842. PubMed ID: 25762012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.